title: Does antiplatelet therapy enhance myocardial salvage after coronary reperfusion?
abstract: The aim of this study was to test the hypothesis that either the cyclooxygenase inhibitor aspirin or the thromboxane A2 receptor antagonist sulotroban exerts a direct myocardial effect that enhances myocardial salvage afforded by reperfusion. Accordingly, 21 anesthetized dogs underwent suture occlusion of the left anterior descending coronary artery. At 2.5 h after occlusion, all dogs received intravenous streptokinase (20,000 U/kg body weight over 30 min) and were randomized to the following groups: group I (n = 7) received no additional treatment, group II (n = 7) received aspirin (5 mg/kg intravenously) and group III (n = 7) received sulotroban (10 mg/kg followed by 10 mg/kg per h intravenously). At 3 h after occlusion, the dogs underwent coronary reperfusion for the next 3 h. Myocardial infarct size as a percent of the hypoperfused zone was similar among dogs in group I (42 +/- 8%), group II (41 +/- 10%) and group III (45 +/- 11%). The incidence and the extent of myocardial hemorrhage were similar in all three study groups. Infarct size as a percent of the hypoperfused zone was significantly smaller in dogs without hemorrhage irrespective of treatment (35 +/- 9% versus 63 +/- 5%, p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107.
authors.forename: Y
authors.initials: Y
authors.lastname: Shi
authors.forename: A
authors.initials: A
authors.lastname: Zalewski
authors.forename: P
authors.initials: P
authors.lastname: Walinsky
authors.forename: S
authors.initials: S
authors.lastname: Goldberg
mesh_terms: D000818:Animals; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D004285:Dogs; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006331:Heart Diseases / Q000139:chemically induced; D006439:Hemodynamics / Q000187:drug effects; D006470:Hemorrhage / Q000139:chemically induced; D009203:Myocardial Infarction / Q000473:pathology*; D015425:Myocardial Reperfusion; D009206:Myocardium / Q000473:pathology*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; C040624:sulotroban; D013300:Streptokinase; D001241:Aspirin